American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.

Medical technology company Becton, Dickinson and Company (NYSE:BDX) will be announcing earnings results tomorrow before market open. Here’s what to look for.

While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key ...

BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $269 from $265 and keeps a Buy rating on the shares after ...

Becton Dickinson (BDX) stock slid 3% after the company released its fiscal Q1 earnings report and confirmed it was splitting the company into two separate entities.

BD plans to separate its Biosciences and Diagnostic Solutions unit into an independent company by fiscal 2026.

Becton Dickinson (BDX) delivered earnings and revenue surprises of 15.10% and 1.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Beldex has made itself a pioneer in privacy-targeted blockchain solutions. Its ecosystem consists of capabilities just like ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences business.